Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezary syndrome: Final results show significant clinical activity and suggest correlation with CD30 expression Meeting Abstract
| Authors: | Kim, Y. H.; Tavallaee, M.; Rozati, S.; Sundram, U.; Salva, K.; Wood, G. S.; Li, S.; Krathen, M.; Nagpal, S.; Reddy, S.; Armstrong, R.; Hoppe, R. T.; Pulitzer, M.; Advani, R. H.; Horwitz, S. M. |
| Abstract Title: | Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezary syndrome: Final results show significant clinical activity and suggest correlation with CD30 expression |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349233802083 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.804.804 |
| Notes: | Meeting Abstract: 804 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
